Preformed albumin corona, a protective coating for nanoparticles based drug delivery system.

The non-specific interaction between nanoparticles (NPs) and plasma proteins occurs immediately after NPs enter the blood, resulting in the formation of the protein corona that thereafter replaces the original NPs and becomes what the organs and cells really see. Consequently, the in vivo fate of NPs and the biological responses to the NPs are changed. This is one substantial reason for the two main problems of the NPs based drug delivery system, i.e. nanotoxicity and rapid clearance of NPs from the blood after intravenous injection. Here, we demonstrate the successful application of the preformed albumin corona in inhibiting the plasma proteins adsorption and decreasing the complement activation, and ultimately in prolonging the blood circulation time and reducing the toxicity of the polymeric PHBHHx NPs. Since the interaction of proteins with various nano-materials and/or -particles is ubiquitous, pre-forming albumin corona has a great potential to be a versatile strategy for optimizing the NPs based drug delivery system.

[1]  Iseult Lynch,et al.  Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. , 2011, Journal of the American Chemical Society.

[2]  Sara Linse,et al.  Understanding the nanoparticle–protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles , 2007, Proceedings of the National Academy of Sciences.

[3]  M. Mahmoudi,et al.  Protein-nanoparticle interactions: opportunities and challenges. , 2011, Chemical reviews.

[4]  Felix Kratz,et al.  Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[5]  Raj Bawa,et al.  Regulating nanomedicine - can the FDA handle it? , 2011, Current drug delivery.

[6]  A. Schätzlein,et al.  Amphiphilic poly(L-amino acids) - new materials for drug delivery. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[7]  Xun Sun,et al.  Mechanisms of phospholipid complex loaded nanoparticles enhancing the oral bioavailability. , 2010, Molecular pharmaceutics.

[8]  R. Tenne,et al.  Inorganic nanotubes and fullerene-like nanoparticles , 2006, Nature nanotechnology.

[9]  S. Feng,et al.  Quantitative control of targeting effect of anticancer drugs formulated by ligand-conjugated nanoparticles of biodegradable copolymer blend. , 2012, Biomaterials.

[10]  R. Jain,et al.  Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner , 2012, Nature nanotechnology.

[11]  Roberto Cingolani,et al.  Effects of cell culture media on the dynamic formation of protein-nanoparticle complexes and influence on the cellular response. , 2010, ACS nano.

[12]  James L. McGrath,et al.  The influence of protein adsorption on nanoparticle association with cultured endothelial cells. , 2009, Biomaterials.

[13]  I. Nabiev,et al.  Molecular interaction of proteins and peptides with nanoparticles. , 2012, ACS nano.

[14]  J. Dordick,et al.  Unfolding of ribonuclease A on silica nanoparticle surfaces. , 2007, Nano letters.

[15]  Mark E. Davis,et al.  Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.

[16]  Kenneth A. Dawson,et al.  Effects of the presence or absence of a protein corona on silica nanoparticle uptake and impact on cells. , 2012, ACS nano.

[17]  Marco P Monopoli,et al.  Biomolecular coronas provide the biological identity of nanosized materials. , 2012, Nature nanotechnology.

[18]  Soft interactions at nanoparticles alter protein function and conformation in a size dependent manner. , 2011, Nano letters.

[19]  Sara Linse,et al.  Detailed identification of plasma proteins adsorbed on copolymer nanoparticles. , 2007, Angewandte Chemie.

[20]  Kenneth A. Dawson,et al.  Protein–Nanoparticle Interactions , 2008, Nano-Enabled Medical Applications.

[21]  A. Schätzlein,et al.  A prodrug nanoparticle approach for the oral delivery of a hydrophilic peptide, leucine(5)-enkephalin, to the brain. , 2012, Molecular pharmaceutics.

[22]  David M. Brown,et al.  The effects of serum on the toxicity of manufactured nanoparticles. , 2010, Toxicology letters.

[23]  K. Dawson,et al.  Systematic investigation of the thermodynamics of HSA adsorption to N-iso-propylacrylamide/N-tert-butylacrylamide copolymer nanoparticles. Effects of particle size and hydrophobicity. , 2007, Nano letters.

[24]  T. Gong,et al.  Injectable and biodegradable thermosensitive hydrogels loaded with PHBHHx nanoparticles for the sustained and controlled release of insulin. , 2013, Acta biomaterialia.

[25]  R. Zhou,et al.  Binding of blood proteins to carbon nanotubes reduces cytotoxicity , 2011, Proceedings of the National Academy of Sciences.

[26]  Iseult Lynch,et al.  The evolution of the protein corona around nanoparticles: a test study. , 2011, ACS nano.

[27]  Kenneth A. Dawson,et al.  Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts , 2008, Proceedings of the National Academy of Sciences.

[28]  C. Hopf,et al.  Identification of serum proteins bound to industrial nanomaterials. , 2012, Toxicology letters.

[29]  V. Yang,et al.  Magnetically-enabled and MR-monitored selective brain tumor protein delivery in rats via magnetic nanocarriers. , 2011, Biomaterials.

[30]  Warren C. W. Chan,et al.  Understanding and Controlling the Interaction of Nanomaterials with Proteins in a Physiological Environment , 2012 .

[31]  Albert Duschl,et al.  Time evolution of the nanoparticle protein corona. , 2010, ACS nano.

[32]  Tao Gong,et al.  A rapid-acting, long-acting insulin formulation based on a phospholipid complex loaded PHBHHx nanoparticles. , 2012, Biomaterials.